Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence^®(1) (denosumab-bnht) and Bomyntra^®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia^®(3) (denosumab) and Xgeva^®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence^®(1)  and Bomyntra^®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia^®(3) and Xgeva^®(4) are registered trademarks of Amgen Inc.

Read the full press release here.

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence^®(1) (denosumab-bnht) and Bomyntra^®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia^®(3) (denosumab) and Xgeva^®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence^®(1)  and Bomyntra^®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia^®(3) and Xgeva^®(4) are registered trademarks of Amgen Inc.

Read the full press release here.

Fresenius‘ Sustainability Advisory Board met at Quirónsalud to experience how digital innovation and value-based healthcare are transforming medical care

Fresenius’ Sustainability Advisory Board (SAB) convened for its second meeting this year, with a focus on how our sustainability ambitions impact patients. Spanning June 2nd and 3rd, Michael Moser, member of the Fresenius management board and responsible for sustainability management, invited the SAB to Madrid, where our external sustainability experts were joined by representatives of the Fresenius Supervisory Board and experts from Group and Quirónsalud.  

“Delivering the highest quality in our products and services – always with a clear focus on patient needs and satisfaction — is a core pillar of our sustainability strategy. It’s inspiring to see how our colleagues at Quirónsalud are embracing digitalization to enhance diagnostics and treatments while elevating the patient experience. We’re not just improving care, we’re transforming it - for the benefit of our patients,“ emphasized Michael Moser.

Firsthand insights into leading healthcare institutions  

During their visit, the participants gained hands-on insights into how our commitment to high-quality, human-centered care is brought to life. They toured two Quirónsalud hospitals, both of which rank among Spain’s leading healthcare institutions: the Jiménez Díaz Foundation University Hospital, with over 90 years of history and a legacy as a pioneer in research and surgery, offering highly specialized, multidisciplinary care; and the University Hospital Rey Juan Carlos, known for its modern infrastructure and patient-focused design, which continues to attract a growing number of patients each year.  

A highlight of the visit was a tour of the operating rooms. There, participants observed how surgical workflows are managed with exceptional precision. Processes are optimized for timing, minimized wait times, improved patient safety, and full traceability through digital health tools. “This high level of efficiency not only ensures excellent clinical outcomes but also enables the hospital to increase the number of patients who trust us year after year, ultimately improving access to care for those who need it,” said Javier Arcos, General Manager of the Fundación Jiménez Díaz.  

Another standout moment was the live demonstration of Casiopea, an integrated digital platform, and Scribe, an AI-powered tool designed to automate doctor-patient interview transcriptions. The implementation of these solutions boosts operational efficiency and enhances the quality of care and patient experience.  

The meeting also focused on Quirónsalud’s strategic approach to quality management and its experience in implementing the Value-Based Healthcare (VBHC) model. This care model is characterized by a holistic treatment approach - enabled by cross-functional collaboration and a consistent focus on treatment outcomes, supported by measurable goals and metrics, and digital tools. Quirónsalud has been implementing this model since 2020.  

Fiona Adshead, member of the SAB and current Chair of the Sustainable Healthcare Coalition, welcomed the company’s efforts: “From my perspective, Quirónsalud is on the right path putting patients at the center of care by embracing the value-based care model. Their inspirational approach of using data and technology to transform care is delivering tangible benefits for patients, optimizing health system resource use, and supporting sustainable business success.”